Brain Tumor Invasion Along Blood Vessels May Lead to New Cancer Treatments, Preclinical Study Suggests
Invading glioblastoma cells may hijack cerebral blood vessels during early stages of disease progression and damage the brain’s protective barrier, preclinical study published in Nature Communications indicated. The finding by Watkins et al could ultimately lead to new ways to bring about the death of the tumor, as therapies may be able to reach these deadly cells at an earlier time point than was previously thought possible.
The blood–brain barrier is designed to stand in the way of harmful materials leaking into the brain and to regulate the transport of important molecules back and forth between the brain and the blood. One component of the blood–brain barrier is close-fitting connections, or tight junctions, that form seals between the blood vessel’s endothelial cells. Several other types of cells cover the blood vessel, including specialized brain cells known as astrocytes, which have extensive endfeet that cover 90% of the blood vessel surface. The astrocytic endfeet release molecules that regulate the tight junctions between the endothelial cells and also release specific chemicals that cause blood vessels to expand or contract, thereby regulating blood flow in the brain.
Study Details
Harald Sontheimer, PhD, from the University of Alabama at Birmingham, and his colleagues investigated the interactions between glioblastoma cells, astrocytes, and cerebral blood vessels. They used mouse models of glioblastoma, fluorescent dyes, and a variety of imaging techniques to see how tumor cells migrate through the brain and interact with other cells and blood vessels.
In the current study, Dr. Sontheimer’s team showed that almost all of the glioblastoma cells outside the main tumor mass were located in the space between the astrocytic endfeet and the blood vessel outer surface. By using the meshwork of small blood vessels as a scaffold, glioblastoma cells were able to migrate along the vessels and extract nutrients from the blood for themselves.
“The vast majority of tumor cells are associated with blood vessels. These cells appear to be using the vessels as highways to travel great distances within the brain,” said Dr. Sontheimer.
In addition, the findings revealed the glioblastoma cells hijacked control over the blood flow by taking it away from the astrocytes. As a result, tight junctions became loose, which led to a breakdown in the blood–brain barrier. Dr. Sontheimer and his colleagues were surprised that very small groups of tumor cells, even individual cells, were sufficient to weaken the blood–brain barrier early in the disease process.
New Perspective on Glioblastoma
“Evidence from our models suggests that early in the disease, invading tumor cells are not completely protected by the blood–brain barrier and may be more vulnerable to drugs delivered to the brain via the blood. If these findings hold true in humans, treatment with anti-invasive agents might be beneficial in newly diagnosed glioblastoma patients,” said Dr. Sontheimer. He added that localized breaches in the blood–brain barrier may allow regionally precise delivery of drugs to attack tumor cells even in the earliest stage.
“Dr. Sontheimer’s findings provide us with new perspectives on how glioblastoma cells successfully invade within the brain and control blood flow to their advantage. These findings have the potential to change current approaches to treating glioblastoma,” said Jane Fountain, PhD, Program Director of the National Institute of Neurological Disorders and Stroke’s brain tumor portfolio.
Further research is needed to learn more about how the blood–brain barrier is regulated and how brain tumor cells take over existing vessels to grow and spread. A better understanding of how tumor cells interact with the blood–brain barrier may increase our ability to treat glioblastoma patients.
Dr. Sontheimer is the corresponding author for the Nature Communications article.
The study was supported by grants from the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health.
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.
